Elise (Dick) Wolf
Gosselin, C., Vorp, D.A., Warty, V., Severyn, D.A., Dick, Elise K., Borovetz, H.S., Greisler. H.P. ePTFE coating with fibrin glue, FGF-1, and heparin: effect on retention of seeded endothelial cells. J Surg Res. 1996 Feb 1; 60(2):327-32.
Norma Vela Roch Syndicated Reports
Strategic Analysis of the U.S. Molecular Cytogenetics Markets, 2009.
Strategic Assessment of World Predictive Toxicology Markets, 2005.
Articles
Jimenez F, Aiba-Masago S, Al Hashimi I, Vela-Roch N, Fernandes G, Yeh C-K, Talal N, Dang H. Activated caspase 3 and cleaved PARP in salivary epithelium suggests a pathogenic mechanism for Sjogrens syndrome (SS). Rheumatol. 41:338-342, 2002.
Aiba-Masago S, Liu X-B, Masago R, Vela-Roch N, Jimenez F, Lau C-M, Frohlich V, Talal N, Dang H. Bax gene expression alters Ca2+ signal transduction without affecting apoptosis in epithelial cell line. Oncogene. 21:2762-2767, 2002.
Nakabayashi T, Sakata K-M, Sakata A, Kong L, Lau A C, Letterio J J, Vela-Roch N, Talal N, Dang H. TGF-β1 null mutation leads to CD154 upregulated expression in affected tissues. Inflammation. 25:69-73, 2001.
Aiba-Masago S, Masago R, Vela-Roch N, Talal N, Dang H. Fas-mediated apoptosis in a rat acinar cell line is dependent on caspase-1 activity. Cell Signal. 13:617-624, 2001.
Liu X-B, Kong L, Masago R, Zhang B-X, Masago S, Vela-Roch N, Katz M S, Yeh C-K, Zhang G H, Talal N, Dang H. G-protein signaling abnormalities mediated by CD95 in salivary epithelial cells. Cell Death Differ. 7:1119-1126, 2000.
Flescher E, Vela-Roch N, Talal N, Dang H. Binding of nuclear proteins to the negative regulatory element of the IL-2gene in lymphocytes from rheumatic patients. Cytokine. 11:187-191, 1999.
Sakata K-M, Sakata A, Vela-Roch N, Kong L, Talal N, Dang H. Monocyte rescue of human T cells from apoptosis is CD40/CD154-dependent. Scand. J. Immunol. 50:479-784, 1999.
Kong L, Ogawa N, McGuff H S, Nakabayashi T, Sakata K-M, Masago R, Vela-Roch N, Talal N, Dang H. Bcl-2 family expression in salivary glands from patients with primary Sjogren’s syndrome: Involvement of Bax in salivary gland destruction. Clin. Immunol. Immunopathol. 33:133-141, 1998.
Sakata K-M, Sakata A, Vela-Roch N, Espinosa R, Escalante A, Kong L, Nakabayashi T, Cheng J, Talal N, Dang H. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes. Eur. J. Immunol. 28:2648-2660, 1998.
Kong L, Robinson C P, Peck A B, Vela-Roch N, Sakata K-M, Dang H, Talal N, Humphreys-Beher M G. Excessive apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin. Exp. Rheumatol. 16:675-682, 1998.
Flescher E, Vela-Roch N, Ogawa N, Nakabayashi , Escalante A, Anaya J-M, Dang H, Talal N. Abnormality of Oct-1 DNA-binding T cells from Sogren’s syndrome patients. Eur. J. Immunol. 26:2006-2011, 1996.
Flescher E, Ledbetter J A, Dang H, Ogawa N, Vela-Roch N, Fossum D, Talal N. Induction of transcription factors in human T lymphocytes by Aspirin-like drugs. Cell. Immunol. 160:232-239, 1995.
Flescher E, Ledbetter J A, Schieven G L, Vela-Roch N, Fossum D, Dang H, Ogawa N, Talal N. Longitudinal exposure of human T lymphocytes to weak oxidative stress suppresses transmembrane and nuclear signal transduction. J. Immunol. 153: 4880-4889, 1994.
.
Nancy Patterson
University of California at Los Angeles, CA, December 1, 2010, Business of Science, Title: Successful Commercialization of Emerging LifeScience Technologies, Los Angeles, CA
Caltech (California Institute of Technology), May 26, 2010, The Biotech Club Industry Night, Keynote Speech, Biotechnology: The Direction of Investments in Biotechnology Innovation, Pasadena, California.
University of California at Los Angeles, CA, April 28, 2010, Business of Science, Title: Successful Commercialization of Emerging LifeScience Technologies, Los Angeles, CA
Webinar: Elsevier Medtech Insight IN3 Webinar Series, December 11, 2009, Title: Avoiding the 14 Biggest Mistakes Made By Emerging Lifescience Companies, Boston MA
Elsevier Medtech Insight Medical Device Investor Forum / IN3 East, Westin Copley Plaza, Boston, MA, June 23, 2009, Title: Setting the Right Trajectory: Avoiding the 14 Biggest Mistakes Made By Emerging Lifescience Companies
University of California at Los Angeles, CA, April 9, 2009, Business of Science, Title: Hot Emerging Biomedical Technologies and Their Successful Commercialization, Los Angeles, CA
Stanford University, Management Science and Engineering 256, May 22, 2009, Title: Early Stage Technology Assessment Palo Alto, California
Hospital Clínic de Barcelona (Dr. Joan Bigorra and LIM Global), December 9, 2008, Title: What’s Hot and What’s Not in Biomedical Technology, Barcelona, Spain
Technion University, December 4, 2008, Title: Exit Strategies for Lifescience Technologies: Determining the Path to Obtain Maximum Value, Haifa, Israel
Biomedical Engineering Society, AIMBE invited presenter, October 3, 2008, Title: AIMBE Public Policy session - Translational BME, St. Louis, MO
University of California at Los Angeles, October. 30, 2008, Business of Science, Title: Presenting Your Compelling Lifescience Technology, Los Angeles, CA,
University of California at Los Angeles, May 30, 2008, Business of Science, Title: Developing a Business Plan for Increased Valuation, Los Angeles, CA
University of California at San Diego, January 14, 2008, Biomedical Engineering, Title: Presenting Your Lifescience Technology: Template for Success, San Diego, CA
Invited presenter, Licensing Executives Society, November 2007, Title: Emerging Biomedical Technologies: Landscape for Successful Technology Selection, Los Angeles, CA
Keynote Speaker, National Academies Round Table, July 17, 2007, Biomedical Engineering Materials and Applications, Title: Surgical Sealants and Tissue Adhesives, Woods Hole, MA
California Institute of Technology, May 2, 2007, Title: Emerging Life Science Technology: From Concept to Reality, Pasadena, California
Invited Speaker, Licensing Executives Society Annual Meeting, February 21, 2007, Title: Emerging Biomedical Technology: What’s Hot and What’s NOT, San Francisco, CA
Stanford University, Kauffman Global Scholars, February 22, 2007, Title: Emerging Lifescience Technology and Successful Commercialization, Palo Alto, CA
University of Washington, Biomedical Engineering, January 20, 2007, Title: Presenting Your Lifescience Technology: Template for Success, Seattle, WA
Keynote speaker, BME Idea, Biomedical Engineering Society Annual Conference, October 11, 2006, Chicago, IL, Title: “Concepts for Commercialization”;
Course developer and Key Presenter, University of California at Irvine, January 13, 2005 - January 27, 2005, Title: Securing Venture Capital Funding for Your Medical Device, Irvine, CA
Vorp, D.A., Gorcsan, J., Mandarino, W.A., Dick, Elise K., Steed, D.L., Webster, M.W. Noninvasive estimation of the biomechanical
properties of the aneurysmal and non-aneurysmal abdominal aorta. Presented at the Association for Academic Surgery Meeting in Albuquerque, New Mexico, November 1994.
Norma Vela Roch
ABSTRACTS (*oral presentation)
Kong L, Vela-Roch N, Talal N, Dang H. Bcl-2 and Bcl-xl inhibit Fas-mediated apoptosis of salivary epithelial cells. Arth. & Rheum. 41:S354, 1998.
*Vela-Roch N, Kong L, Talal N, Dang H. Sulphasalazine and its metabolites may mediate their therapeutic effects through apoptosis. Arth. & Rheum. 41:S160, 1998.
Sakata K-M, Sakata A, Kong L, Vela-Roch N, Talal N, Dang H. Monocytes rescue T cells from apoptosis is CD40/CD40L-dependent and not impaired in patients with Systemic Lupus Erythematosus. Arth. & Rheum. 41:S42, 1998.
Sakata K-M, Sakata A, Dang H, Vela-Roch N, Ecalante A, Kong L, Nakabayashi T, Cheng J, Talal N. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes activation. Arth. & Rheum. 39:S141, 1996.
Flescher E, Dang H, Vela-Roch N, Ogawa N, Talal N. Defective binding to specific enhancer sequences in primary but not secondary Sjogren’s syndrome (SS). Arth. & Rheum. 37:S285, 1994.
Flescher E, Vela-Roch N, Escalante A, Talal N. The Oct-1 transcription factor abnormality in Sjogren’s syndrome (SS) is correctable by dephosphorylation and does not occur in systemic lupus erythematosus (SLE). Arth. & Rheum. 36:S43, 1993.
Flescher E, Vela-Roch N, Talal N. Decreased expression of the Oct-1 transcription factor regulating the T cell interleukin-2 (IL-2) gene in Sjogren’s syndrome. Arth. & Rheum. 35:S61, 1992.
